Cargando…

Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)

Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations of ML-II. Since the mechanisms underlying these s...

Descripción completa

Detalles Bibliográficos
Autores principales: KÖSE, Sevil, AERTS KAYA, Fatima, KUŞKONMAZ, Barış, UÇKAN ÇETİNKAYA, Duygu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620033/
https://www.ncbi.nlm.nih.gov/pubmed/31320815
http://dx.doi.org/10.3906/biy-1902-20
_version_ 1783433978843234304
author KÖSE, Sevil
AERTS KAYA, Fatima
KUŞKONMAZ, Barış
UÇKAN ÇETİNKAYA, Duygu
author_facet KÖSE, Sevil
AERTS KAYA, Fatima
KUŞKONMAZ, Barış
UÇKAN ÇETİNKAYA, Duygu
author_sort KÖSE, Sevil
collection PubMed
description Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations of ML-II. Since the mechanisms underlying these skeletal defects in ML-II are not completely understood, we hypothesized that a defect in osteogenic differentiation of ML-II bone marrow mesenchymal stem cells (BM-MSCs) might be responsible for this skeletal phenotype. Here, we assessed and characterized the cellular phenotype of BM-MSCs from a ML-II patient before (BBMT) and after BM transplantation (ABMT), and we compared the results with BM-MSCs from a carrier and a healthy donor. Morphologically, we did not observe differences in ML-II BBMT and ABMT or carrier MSCs in terms of size or granularity. Osteogenic differentiation was not markedly affected by disease or carrier status. Adipogenic differentiation was increased in BBMT ML-II MSCs, but chondrogenic differentiation was decreased in both BBMT and ABMT ML-II MSCs. Immunophenotypically no significant differences were observed between the samples. Interestingly, the proliferative capacity of BBMT and ABMT ML-II MSCs was increased in comparison to MSCs from age-matched healthy donors. These data suggest that MSCs are not likely to cause the skeletal phenotype observed in ML-II, but they may contribute to the pathogenesis of ML-II as a result of lysosomal storage-induced pathology.
format Online
Article
Text
id pubmed-6620033
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Scientific and Technological Research Council of Turkey
record_format MEDLINE/PubMed
spelling pubmed-66200332019-07-18 Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease) KÖSE, Sevil AERTS KAYA, Fatima KUŞKONMAZ, Barış UÇKAN ÇETİNKAYA, Duygu Turk J Biol Article Mucolipidosis type II (ML-II, I-cell disease) is a fatal inherited lysosomal storage disease caused by a deficiency of the enzyme N-acetylglucosamine-1-phosphotransferase. A characteristic skeletal phenotype is one of the many clinical manifestations of ML-II. Since the mechanisms underlying these skeletal defects in ML-II are not completely understood, we hypothesized that a defect in osteogenic differentiation of ML-II bone marrow mesenchymal stem cells (BM-MSCs) might be responsible for this skeletal phenotype. Here, we assessed and characterized the cellular phenotype of BM-MSCs from a ML-II patient before (BBMT) and after BM transplantation (ABMT), and we compared the results with BM-MSCs from a carrier and a healthy donor. Morphologically, we did not observe differences in ML-II BBMT and ABMT or carrier MSCs in terms of size or granularity. Osteogenic differentiation was not markedly affected by disease or carrier status. Adipogenic differentiation was increased in BBMT ML-II MSCs, but chondrogenic differentiation was decreased in both BBMT and ABMT ML-II MSCs. Immunophenotypically no significant differences were observed between the samples. Interestingly, the proliferative capacity of BBMT and ABMT ML-II MSCs was increased in comparison to MSCs from age-matched healthy donors. These data suggest that MSCs are not likely to cause the skeletal phenotype observed in ML-II, but they may contribute to the pathogenesis of ML-II as a result of lysosomal storage-induced pathology. The Scientific and Technological Research Council of Turkey 2019-06-13 /pmc/articles/PMC6620033/ /pubmed/31320815 http://dx.doi.org/10.3906/biy-1902-20 Text en Copyright © 2019 The Author(s) This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Article
KÖSE, Sevil
AERTS KAYA, Fatima
KUŞKONMAZ, Barış
UÇKAN ÇETİNKAYA, Duygu
Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title_full Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title_fullStr Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title_full_unstemmed Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title_short Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
title_sort characterization of mesenchymal stem cells in mucolipidosis type ii (i-cell disease)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620033/
https://www.ncbi.nlm.nih.gov/pubmed/31320815
http://dx.doi.org/10.3906/biy-1902-20
work_keys_str_mv AT kosesevil characterizationofmesenchymalstemcellsinmucolipidosistypeiiicelldisease
AT aertskayafatima characterizationofmesenchymalstemcellsinmucolipidosistypeiiicelldisease
AT kuskonmazbarıs characterizationofmesenchymalstemcellsinmucolipidosistypeiiicelldisease
AT uckancetinkayaduygu characterizationofmesenchymalstemcellsinmucolipidosistypeiiicelldisease